Created as a part of the OHSU Knight Cancer Institute, the Immune Monitoring & Cancer Omics Program seeks to provide seamless support and wide-ranging analytics for clinical and translational studies. The primary objective of the IMCO platform is to provide our clients with a comprehensive offering of state of-the-art research and CLIA assays generating data that leads to improved or new standards in patient care.  We offer end to end process in which we manage sample acquisition, preparation, assay execution and data generation. All of our offerings including research assays are conducted under good laboratory practices and internally validated.


Patient Tumor IMCO page

The IMCO comprehensively characterizes immune responses to determine mechanisms of resistance and develop biomarkers to predict therapeutic outcomes or toxicities. Our program is designed is to work closely with individual partners to deliver the services needed for each specific study.

IMCO Specimen Management



Assays custom packaged IMCO page


IMCO Panel of Scientific Advisors:
Experts


The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials.

Learn More